Orca Capital AG reduced its ownership in Rani Therapeutics Holdings, Inc. (RANI) by 56.55% as of July 23, 2025, decreasing its holdings from 4,354,000 shares to 1,891,623 shares, as reported in a 13G/A filing.1 This significant reduction coincided with a period of capital-raising activities by Rani Therapeutics.
Key factors that likely contributed to Orca Capital AG's decision include:
- Registered Direct Offering: In July 2025, Rani Therapeutics announced a registered direct offering to a single institutional investor for the purchase and sale of 4,354,000 shares of its Class A common stock at $0.40 per share, along with pre-funded warrants.2 The timing of Orca Capital AG's ownership reduction closely aligns with this offering, suggesting a potential strategic divestment or re-evaluation of their position in light of new capital entering the company.
- Company's Financial Position: Rani Therapeutics had been experiencing a notable cash burn. As of December 31, 2024, the company expected its cash, cash equivalents, and marketable securities to fund operations only into the third quarter of 2025 without additional funding.3 By June 30, 2025, cash, cash equivalents, and marketable securities had decreased to $10.2 million from $27.6 million at the end of 2024.2 This financial trajectory indicates a need for capital, which the direct offering aimed to address. Investors may adjust their positions when a company undertakes capital raises, particularly if it implies dilution or a reassessment of the company's financial health and future prospects.
While the exact motivations for Orca Capital AG's specific portfolio decisions are not publicly detailed, the confluence of their significant share reduction and Rani Therapeutics' capital-raising activities around the same time suggests a direct relationship.
